GlaxoSmithKline has retained its leading position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
The Access to Medicines Index, published every 2 years, ranks 20 of the world’s largest pharmaceutical companies according to their work in this area.
The bottom 5 companies are named as Bayer, Abbvie, Daiichi Sankyo, Astellas, and Eli Lilly. out of these five, only Bayer and Eli Lilly have strategies in place for improving access to drugs.
The 2018 Access to Medicine Index list – which measures the performance of the leading 20 pharma companies across 7 different categories, such as access-to-medicine management, R&D and pricing – also saw Novartis move into second place, ahead of Johnson & Johnson and Merck KGaA, while Takeda jumped 10 places to take the fifth spot.
We are pleased to have ranked 1st and improved our score in the Access to Medicine Index list. We are excited to welcome the recognition for having the largest proportion of our R&D pipeline dedicated to priority diseases and for the creation of an integrated Global Health R&D unit to stimulate collaboration Phil Thomson, president of Global Affairs at GSK.
The list also revealed that the 4 leading pharmas in this area, together with Sanofi (in 6thplace), account for 63% of the priority research and development being undertaken.
The Index also brings in focus that the industry’s engagement in such R&D is focused on 5 diseases, with half of all such activity targeting malaria, HIV/AIDS, tuberculosis, malaria, Chagas disease and leishmaniasis.
The analysis shown that the majority of the priority R&D projects are being carried out with public sector research organisations, but few companies are developing priority products without such facilitation, such as Merck KGaA with its work on tests and treatment for schistosomiasis, the group noted.
Thank you for reading : GSK retains top position on the Access to Medicines Index, Now Also read :